Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib
European Journal of Dermatology · 2023
DOI: 10.1684/ejd.2023.4461 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Dermatology, 2023. Verfasst von Xiaohong Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The University of Hong Kong Shenz hen Hospital, Shenzhen, China 518053. Hauptthemen laut MEDLINE: Acrodermatitis, Exanthema. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib Acrodermatitis continua of Hallopeau (ACH) is a rare subtype of pustular psoriasis that presents as a sterile,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The University of Hong Kong Shenz hen Hospital, Shenzhen, China 518053.
- Department of Rheumatology, The University of Hong Kong Shenzhen Hospital, Shenzhen, China 518053.
Zitieren
APA
Chen, X., Huang, X., Ma, L., Wang, B., Tian, J., & Liu, X. (2023). Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib. European Journal of Dermatology. https://doi.org/10.1684/ejd.2023.4461
Vancouver
Chen X, Huang X, Ma L, Wang B, Tian J, Liu X. Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib. European Journal of Dermatology. 2023. doi:10.1684/ejd.2023.4461
BibTeX
@article{Chen2023,
author = {Chen, Xiaohong and Huang, Xiaoyan and Ma, Li and Wang, Bin and Tian, Jiabin and Liu, Xiaoming},
title = {Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib},
journal = {European Journal of Dermatology},
year = {2023},
doi = {10.1684/ejd.2023.4461}
}
EUVIMED